New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
07:41 EDTBIIBBiogen drops 7% after ALS drug misses endpoint in trial
Shares of Biogen Idec (BIIB) are down 7% in pre-market trading after the company said its Phase 3 trial investigating dexpramipexole in people with amyotrophic lateral sclerosis, or ALS, did not meet its primary endpoint. Biogen said it will discontinue development of dexpramipexole in ALS due to the trial results. Note earlier this morning, Piper Jaffray cut its rating on shares of Biogen to Neutral from Overweight. The stock is currently trading lower 7%, or $10.01, to $139.99 in pre-market trading.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
08:01 EDTBIIBPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 9, 2014
12:22 EDTBIIBPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use